Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

ARE

Insights on Investing in ARE – Expert Analysis

Alexandria Real Estate Equities logged a -0.0% change during today's afternoon session, and is now trading at a price of $77.81 per share. The S&P 500 index moved -1.0%. ARE's trading volume is 1,807,092 compared to the stock's average volume of 1,349,345.

Alexandria Real Estate Equities trades -33.24% away from its average analyst target price of $116.54 per share. The 13 analysts following the stock have set target prices ranging from $100.0 to $144.0, and on average have given Alexandria Real Estate Equities a rating of buy.

Anyone interested in buying ARE should be aware of the facts below:

  • Alexandria Real Estate Equities's current price is 18.7% above its Graham number of $65.57, which implies that at its current valuation it does not offer a margin of safety

  • Alexandria Real Estate Equities has moved -40.0% over the last year, and the S&P 500 logged a change of -2.8%

  • Based on its trailing earnings per share of 1.8, Alexandria Real Estate Equities has a trailing 12 month Price to Earnings (P/E) ratio of 43.2 while the S&P 500 average is 29.3

  • ARE has a forward P/E ratio of 22.6 based on its forward 12 month price to earnings (EPS) of $3.44 per share

  • Its Price to Book (P/B) ratio is 0.75 compared to its sector average of 2.15

  • Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world.

  • Based in Pasadena, the company has 552 full time employees and a market cap of $13.46 Billion. Alexandria Real Estate Equities currently returns an annual dividend yield of 6.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS